May Han

Inversor de Capital Privado en Cure Ventures Management LP .

Consumer Services

Health Technology

Finance

Perfil

May Han is currently a Partner at Cure Ventures Management LP since 2021.
Prior to this, she worked as a Director at Novartis AG from 2013 to 2021 and as a Director at AVEO Pharmaceuticals, Inc. from 2003 to 2012.
Dr. Han received her undergraduate degree from Peking University in 1990 and her doctorate degree from Yale University in 1996.

Cargos activos de May Han

Empresas	Cargo	Inicio
Cure Ventures Management LP Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts.	Inversor de Capital Privado	01/09/2021

Todos los cargos activos de May Han

Antiguos cargos conocidos de May Han.

Empresas	Cargo	Fin
NOVARTIS AG	Director/Miembro de la Junta	30/09/2021
AVEO PHARMACEUTICALS, INC.	Director/Miembro de la Junta	30/06/2012

Ver el detalle de la experiencia de May Han.

Formación de May Han.

Peking University	Undergraduate Degree
Yale University	Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de May Han.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
NOVARTIS AG	Health Technology

Empresas privadas	2
Cure Ventures Management LP Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts.	Finance
AVEO Pharmaceuticals, Inc. AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.	Health Technology